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Abstract
Introduction. Locally advanced breast cancer is a quite common clinical scenario in the developing countries where the recurrence remains a
problem. Mastectomy is one of the primary treatment. Age, clinical stage, lymph nodes involvement, histopathlogy, tumor grading and its subtypes
are thought as clinic histopathologic factors influencing the recurrence. We run a study aimed to find out role of these factors on the recurrence
after mastectomy.
Method. The study designed as an analytical cross–sectional one. A complete data of all patients treated in dr. Cipto Mangunkusumo General
Hospital with locally advanced breast cancer underwent mastectomy with appropriate definitive treatment to the stage, and had disease free interval,
and could be followed for at least 24 months during period of January 2011 to December 2012 is recorded.
Results. There were 39 subjects enrolled. Among these subjects, the recurrence was 7.6%. Through bivariate analysis we found a significant
correlation between the histopathology type (p = 0.008), lymph nodes involvement (p = 0.026) with the recurrence. In multivariate analysis we
found that the most influential factor to reccurrence was lymph node involvement (p = 0.002).
Conclusion. In this study the most influential factor on the recurrence in locally advanced breast cancer following mastectomy is positive lymph
nodes more than three nodes.
Keywords: locally advanced breast cancer, mastectomy, recurrence, clinicohistopathologic

Introduction
Nowadays, breast cancer found to be the most malignancy found in
women all over the world.1 Annually, it thought to be found 1.3
million new breast cancer worldwide.2 In Indonesia breast cancer is
the most malignancy found in women with the incidence of 36.2 per
100.000 population with mortality rate of 18.6 per 100.000
population (Globocan 2008 estimation). More than 50% breast
cancer found referred to advanced stage.3
With treatment consideration, breast cancer were classified into two
major groups, i.e. early and advanced stage. The advanced one is
further classified into two main group, i.e. locally advanced (LABC)
and metastasis. LABC is characterized with mass of a quite large
tumor measured more than five cm, skin involvement and or anterior
chest, and fixed axillary ipsilateral lymph nodes, internal mammary
ipsilateral with no distance metastasis.4 LABC refers as a most found
clinical scenario in the developing countries as in Asia;5 it is probably
related to social and economic status as well as low educated grade.
This kind of treatment of LABC is to control of loco regional and
systemic spreading of the tumor; both consist of multimodal therapy
such as surgical intervention, irradiation therapy, chemotherapy and
hormonal therapy. To date, mastectomy referred to main treatment;
either classic radical or modified radical one.6

Recently, the mortality rate has been decreased compared to those in
period of 1980s, a period that the mortality rate of breast cancer
reached its summit (in the era of 1971–1975, the five–year survival
rate reached of 52%, and was increasing up to 80% in year of 2003),7
and this descend found to be correlated to a number of factors such as
a well campaigned cancer screening as a main contributor, as well as
a well–developed multidisciplinary approach.8 Nevertheless, this
descend of mortality rate was paralleled to a better life expectancy of
breast cancer patients particularly in the developing countries.9
Unfortunately, the recurrence both of loco regional and distance type
remain the problem encountered. The recurrence referred to a
condition of clinical manifested of a cancer which is previously
treated definitively and healed. There’s a condition, should be a
period between and known as disease–free interval. The spread of
tumor, incomplete tissue removal both of local and regionally might
responsible to the recurrence (Donegan, 1979). The incidence of the
recurrence (both of local and regional/loco regional) is 12% in 10
years period following mastectomy.
Yet, there are known prognostic factors influencing the recurrence,
such as clinical (age, clinical stage, lymph nodes status) and
histopathologic (tumor types, grade, and tumor subtypes). For this
reason, we run a study aimed to find out the role of these prognostic
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factors in the recurrence of LABC following mastectomy in our
center.
Method
A study of cross sectional analytic is carried out in March to May
2013 in surgical oncology division, department of surgery, dr. Cipto
Mangunkusumo hospital Jakarta. Data of subjects with breast cancer
available from medical record. The target population was those with
local advanced breast cancer. Reached population was those who
completed mastectomy and definitive treatment in accordance with
the tumor stage and otherwise healed, had a disease–free interval and
feasible to be followed for a minimal of 24 months in period of
January 2011 to December 2012. Included samples (stage IIIA, IIIB,
IIIC) were enrolled using convenience sampling method with
consideration to a complete medical record. The variables were age,
type of histopathology findings, clinical stage, involvement of lymph
nodes, grade of cell differentiation, subtype of tumor, and recurrence
(local, regional and distance metastasis). Verified data were subjected
to statistical analysis using SPSS 17.0 for windows. Ethical
committee of FMUI and research bureau of dr. Cipto
Mangunkusumo General Hospital approved the study.

Results
There were 758 subjects diagnosed as breast cancer, 324 with LABC,
and 39 subjects who met the criteria. Out of these subjects, the mean
rate of follow up was 30 months. Thirty three subjects underwent
neoadjuvant chemotherapy, and the rest of 6 subjects underwent
adjuvant chemotherapy. Twenty eight underwent modified radical
mastectomy (MRM), and 18 subjects underwent classic radical
mastectomy (CRM). All these subjects were irradiated, whilst
hormonal therapy found administered in 21 subjects.
In this study we found 3 subjects (7.6%) recurrent; first two subjects
were locally and the other one with distance metastasis. The subjects
age mostly of age group of more than 35 years (38 subjects, 97.4%).
Regarding the histopathology findings, ductal invasive type referred
to the most often found (31 subjects, 79.5%). The other types were
medullary (10.3%), lobular invasive (7.7%), and mixed of lobular
and ductal invasive (2.6%). Number of lymph nodes involved mostly
found were less than three (18 subjects, 46.2%), and positive lymph
nodes more than three found in four subjects (10.3%), whilst 17
subjects no data. The histopathologic grading found were grade 1 and
2 (26 subjects, 66.7%) and grade 3 found in 13 subjects (33.3%).
Clinical staging of 3B found in 33 subjects, 84.6%) and 3A in 6
subjects, 15.4%). Tumor subtype luminal A found in 16 subjects
(41.4%), luminal B found in 5 (12.8%), positive HER2 found in 4
subjects (10.3%), and basal type found in 7 subjects (17.9%).
Statistical analysis using Chi–square (unpaired comparative
hypothesis) and Fisher test (the alternative of Chi–square). Lymph
nodes more than three is thought to have a correlation with the
recurrence. Based on this statistical analysis, it was concluded that
there is a different proportion of the recurrence between subjects with
positive lymph nodes more than three with those less than three (p =
0.026). The different is represented by OR of 2 (95%CI 0.751–
5.329), meaning that subject with lymph nodes more than three found
to be exposed to the recurrence two times than those with lymph
nodes less than three.

In the study we found 38 subjects aged more than 35 years old
(92.1%), and unsurprisingly we found that the recurrence found in
subjects aged more than 35 years old. Statistical analysis showed p
value of 0.923, which was, with α valued of 5% it could be concluded
that there was no significant difference between the recurrence in the
group more than 35 and less than 35 years old.
The trend or the proportion of the recurrence from the perspective of
histopathology findings was ductal invasive, lobular invasive, mixed
of lobular invasive with ductal invasive, and medullary were 0%,
33.7%, 0%, and 50%. Chi–square test showed that there was a
significant correlation between histopathology findings with the
recurrence (p = 0.008).
Regarding tumor subtype, luminal A, luminal B, HER2 positive, and
basal, proportion of the recurrence were 0%, with exception to basal
subtype which was 26.6%. Chi–square test showed no significant
difference between tumor subtype with the recurrence (p = 0.091).
Statistical analysis showed that there was no different of proportion
between the recurrence with clinical stage of 3A and 3B (p = 0.579).
The proportion of the recurrence in low grade tumor (grade 1 and 2)
was 15.4%, whilst in high grade (grade 3) was 3.8%. Chi–square test
showed there were no significance between tumor grade with the
recurrence (p = 0.597).
There were four variables with p–value less than 0.25, which was
histopathology findings, lymph nodes involvement, tumor grade and
subtype, respectively. Those variables subjected to multivariate
analysis, aimed to find out the determinant model to the recurrence.
In this kind of model, all variables candidate were included together.
The exclusion of these candidates commenced with those with the
larger p–value. Thus, we found that histopathology findings with the
largest p–value, and in the further process this variable was left
behind. Further, the variable of tumor subtype then excluded. Thus,
we found lymph nodes involvement referred to the variable with p–
value below of 0.05, means that this variable correlated significantly
with the recurrence.
Discussion
The recurrence of LABC in accordance to the criteria managed in our
hospital during period of January 2011 to December 2012 is 7.6%,
found to be like study of Lertsanguansinchai and his coworkers of
5.1%.5,8
Those aged less than 35 years old referred to the risk group of the
recurrence13,14,15 as in the older age group were at risk to the higher
tumor grades, negative ER/PR, and showed a trend to have
lymphovascular invason.13.14 Meanwhile in those up to 70 years old
shoed a poor outcome as there were comorbid found.15 However, in
the study we found age referred to a variable showed no significant
to the recurrence.
There are published studies proposed that clinical stage referred as the
prognostic tool in prediction of the recurrence.14,15 However, in the
study we found the most often stage is 3B (84.6%), whilst 3A is just
15.4%; like those reported by Kheradmand and colleagues.
Ductal invasive carcinoma referred to the most often histopathology
findings found in 79.5% subjects and slightly higher than ever
reported (70%).15 This ductal invasive carcinoma showed a poor
prognosis with 10 years survival less than 50%. And this was found
in conjunction with mixed of ductal and lobular, which was found in
8

2.6% subjects as lobular invasive found in 7.7% subject. We found
also medullary carcinoma in 10.3% subject which reported to have
poor prognosis.15 There are 10.3% subjects with lymph nodes
involvement more than three found in who have a probability two
times to have recurrence.
Grade 2 found in 64.1% subjects, grade 3 as much as 33.3% and
grade 1 of 2.6% different to those reported by Kheramand and
coworkers who found that the most often found recurrence in grade
3 (69.56%), grade 2 (47.82%), and grade 1 (8.6%), respectively. The
higher grade correlated to lower long term survival rate. In the study
we found grade 3 significantly correlated with the recurrence.
Biological characteristics of ER and PR were represented with
subtype of breast cancer in accordance to findings of Sorlie et.al.13 as
combined with HER2/neu. Based on this subtype of breast cancer,
type of basal–like/ triple negative with ER, PR and negative
HER2/neu will have characteristically the most aggressive with quite
low disease free survival and overall survival.
The six factors analyzed, there are two factors showed significances.
Somehow, the tumor subtype showed a trend to significant with p–
value of 0.091. This tumor subtype referred to a factor influencing
greatly to the recurrence. The p–value showed a trend to significance
tells us of inadequacy in the number of enrolled samples. This was
found to be in the same boat with non–significance variables, i.e. age,
tumor stage, and tumor grade, as the study focused to LABC, and
those who presented in our hospital with recurrence have their
characteristics indifferent to those with no recurrence. The
predominant age group of less than 35 years old (97.4%), grade 1–2
(66.7%), clinical stage of 3B (84.6%).
Through staged analysis of factors that met the criteria of multivariate
analysis, we found that lymph nodes involvement showed a p–value
of 0.002 and referred to a prognostic factor significantly correlated
with the recurrence of LABC following mastectomy. This positive
regional lymph nodes involvement referred to predictive to distant
metastasis.13 It was estimated that 80% of metastasis malignant solid
tumor such as breast cancer as well as melanoma spreads through
lymphatic drainage, whilst just 20% through hematogenous or
directly spreads.18 It is believed that most tumor cells directly
penetrates to lymph nodes rather than impenetrate the efferent
lymphatic or vein system through lymphatic–venous junction.
Studies shown this junction within the nodes utilize oxygen and or
bacteria, radioactive chromium, and radio opaque contrast material.17
Wills and coworkers in their thorough histopathology study found
that the tumor hematologic dissemination preceded through
lymphatic branches to the veins system within the lymph node.17
Recent studies demonstrated tumor cytokine–induced angiogenesis
and lymph angiogenesis of sentinel nodes, cues an anatomical
pathway of tumor cells within the nodes to be migrated from the
lymphatic vessels to surrounding veins, though such a pathway is not
well documented yet.17According to Alitalo and Detmar, an exact
exit route of metastasis remains an issues to be investigated further,
but they believed in the near future cell labeling during the transit
enlightens the particular route of the metastasis.18 Tachibana and
Yoshida believes that the regional nodes roles out as a transient
barrier to reject a small number of tumor cells during the early phase
of tumor development, and or following primary tumor removal; and
plays an important role in maintaining the immunity against cancer.
However, once the activity of suppressor is induced in regional

nodes, the growth of the local tumor referred to a stimulus of
excessive antigen within the nodes. Continues production of T cell
suppressor within the nodes as the insults of this excessive antigen
stimulation will facilitates the development of metastasis and vice
versa. This explains that with the tumor spreading to the regional
nodes could be used as a modality in predicting the local recurrence.
The issue of prognosis is not as conventional as the variables used in
the study. Nowadays, the challenging issue of genetic take over.
There are a lot of recent prognostic factors such as S–phase, Ki–67,
u–PA, PAI–1, angiogenesis, metastasis occult, and gen profile
expression is not the focus of a study yet.
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